PIAS1 (protein inhibitor of activated STAT, 1)

Andrea Rabellino, Pier Paolo Scaglioni

Division of Hematology and Oncology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA (AR, PPS)

Published in Atlas Database: July 2013

Online updated version: http://AtlasGeneticsOncology.org/Genes/PIAS1ID45688ch15q23.html
DOI: 10.4267/2042/53083

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on PIAS1, with data on DNA/RNA, on the protein encoded and where the gene is implicated.

Identity

Other names: DDXBP1, GBP, GU/RH-II, ZMIZ3
HGNC (Hugo): PIAS1
Location: 15q23


Note

PIAS1 gene was initially located at 15q22 (Weiskirchen et al., 2001).

DNA/RNA

Description

PIAS1 gene is composed of 14 exons and spans approximately 134.8 kb of genomic DNA.

Transcription

PIAS1 gene encodes a 2309 bp mRNA transcript.

Pseudogene

No pseudogenes have been reported.

Protein

Description

The human PIAS1 protein is composed of 651 amino acids, with a predicted molecular weight of 71.85 kDa. PIAS1 has five distinct functional domains, with different functions: the SAP (scaffold attachment factor-A/B, Acinus and PIAS), the PINIT motif, the RING-type zinc-binding domain, the SBD (SUMO binding domain, also indicated as SIM, SUMO interacting motif) and a C-terminal serine/threonine rich region.

The SAP domain contains a LXXLL motif which is involved in direct-DNA binding or in physical interaction with other proteins involved in DNA-binding, such as transcription factors, co-regulators and nuclear receptors (Aravind and Koonin, 2000). The PINIT motif is involved in the sub-cellular organization of PIAS1 (Duval et al., 2003). The RING domain is essential for the E3 SUMO-ligase activity of PIAS1 and also mediates protein-protein interactions (Hochstrasser, 2001). The SBD domain interact in a non-covalently way with SUMO proteins (Rytinki et al., 2009).
PIAS1 (protein inhibitor of activated STAT, 1) Rabellino A, Scaglioni PP

Structural organization of PIAS1 human gene.

Schematic representation of PIAS1 protein. The different domains are illustrated. A purple square represents the SUMO binding domain (SBD).

The C-terminal portion of PIAS1 is a serine/threonine rich region: this is the most variable region within the PIAS proteins family. PIAS1 undergoes several post-translational modifications, including phosphorylation, acetylation, methylation, SUMOylation and ubiquitination (Liu et al., 2005; Depaux et al., 2007; Rytinki et al., 2009; Stehmeier and Muller, 2009; Weber et al., 2009).

**Expression**
PIAS1 is ubiquitously expressed.

**Localisation**
Nuclear.

**Function**
PIAS1 has been implicated in several cellular functions and most of them have been associated to its SUMO E3-ligase activity (Schimdt and Muller, 2003; Shuai and Liu, 2005; Rytinki et al., 2009).

**Transcriptional regulation:** PIAS1 is a negative regulator of several transcription factors. PIAS1 was initially described as a negative regulator of the STAT1 signal by blocking the DNA-binding activity of STAT1 (Liu et al., 1998). PIAS1 SUMOylates the TP53 tumor suppressor, inhibiting its activity (Kahyo et al., 2001; Schimdt and Muller, 2002). PIAS1 SUMOylates the androgen receptor (AR) repressing the AR-dependent transcription (Nishida and Yasuda, 2002). PIAS1 also regulates the homeoprotein Msx1 by regulating its subnuclear localization and its DNA-binding specificity in a SUMO E3-ligase independent manner (Lee et al., 2006). PIAS1 SUMOylates the progesterone receptor (PR), and cAMP attenuates ligand-dependent SUMOylation of PR (Jones et al., 2006).

**Inflammation and immunity:** upon various inflammatory stimuli, IKKα phosphorylates PIAS1 associating it with the promoter of NF-κB target genes (Liu et al., 2007). PIAS1 regulates the natural T regulatory cells by restricting their differentiation through the recruitment of the protein DNA-methyltransferase and CBX5 at the FOXP3 promoter (Liu et al., 2010).

**DNA damage:** PIAS1 co-operates with PIAS4 promoting double-strand DNA breaks repair (Galanty et al., 2009).

**Cancer:** PIAS1 SUMOylates the promyelocytic leukemia (PML) gene and promotes its ubiquitin/proteasome-dependent degradation, inhibiting its tumor suppressor functions. PIAS1 also SUMOylates the PML-RARA oncoprotein of acute promyelocytic leukemia (APL); in this case, PIAS1-dependent SUMOylation is required for the degradation of PML-RARA in APL cells treated with arsenic trioxide (Rabellino et al., 2012).

**Homology**
PIAS1 belongs to the PIAS proteins family and is evolutionary conserved from yeast to man. PIAS1 can be found in Saccharomyces cerevisiae, in plants (Arabidopis thaliana and Oryza sativa), Caenorhabditis elegans, Drosophila melanogaster, Danio renio, Xenopus laevis, Gallus gallus and mammals. All PIAS1 orthologues share a high degree of homology.

The human PIAS family consists of at least 5 different members: PIAS1, PIAS2 (with two variants called PIASxα and PIASxβ), PIAS3 and PIAS4 (also known as PIASy). All family members share high protein homology, except for the C-terminus (Shuai and Liu, 2005; Rytinki et al., 2009).
Schematic representation of the mutations of human PIAS1 protein found in tumor samples. Notably, most of the mutations reside in the PINIT domain.

**Mutations**

**Note**
No translocations involving PIAS1 gene have been reported so far.

**Germinal**
No germinal mutations of PIAS1 have been reported.

**Somatic**
At least 25 different somatic mutations have been described in different tumor types. All the informations in this regard can be found at the COSMIC website.

**Implicated in**

**Prostate cancer**

**Note**
High expression of PIAS1 is found in malignant areas of prostate cancer as compared to benign areas. Immunohistochemistry staining positively correlates with positive staining for the PCNA and Ki-67 proliferative markers suggesting a pro-proliferative role of PIAS1 in prostate cancer (Hoefer, 2012).

**Colon cancer**

**Note**
Activated STAT3 signaling has been involved in colon cancer. PIAS1 is a negative regulator of the STAT signaling. Accordingly, PIAS1 expression is high in colonic non-tumor cells and adenomas, and lower in colon cancer cells (Coppola et al., 2009).

**Gastric cancer**

**Prognosis**
One study shows that 70% of the gastric tumors specimens analyzed show a low level of PIAS1 expression. Moreover, the low expression of PIAS1 significantly correlates with tumor staging (Chen et al., 2012).

**Non-small cell lung cancer (NSCLC)**

**Note**
PIAS1-dependent SUMOylation of PML leads to its degradation, blocking the tumor suppression activity of PML. Accordingly with this observation obtained with in vitro experiments, a correlation between high level of PIAS1 protein expression and low level of PML was reported in NSCLC specimens.

Furthermore, high expression of mRNA levels of PIAS1 in NSCLC specimens correlates with PIAS1 gene amplification (Rabellino et al., 2012).

**Breakpoints**

**Note**
None.

**References**


Nishida T, Yasuda H. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem. 2002 Nov 1;277(44):41311-7


Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. J Cancer Res Clin Oncol. 2009 Sep;135(9):1287-91


Steheiner P, Muller S. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell. 2009 Feb 13;33(3):400-9


This article should be referenced as such: